Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) - Net Assets
Based on the latest financial reports, Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) has net assets worth $482.83 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($501.01 Million) and total liabilities ($18.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $482.83 Million |
| % of Total Assets | 96.37% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Drugs Made In America Acquisition II Corp. Ordinary Shares - Net Assets Trend (2024–2024)
This chart illustrates how Drugs Made In America Acquisition II Corp. Ordinary Shares's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Drugs Made In America Acquisition II Corp. Ordinary Shares (2024–2024)
The table below shows the annual net assets of Drugs Made In America Acquisition II Corp. Ordinary Shares from 2024 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-116.72K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Drugs Made In America Acquisition II Corp. Ordinary Shares's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.44K | % |
| Other Components | $33.56K | % |
| Total Equity | $-116.72K | 100.00% |
Drugs Made In America Acquisition II Corp. Ordinary Shares Competitors by Market Cap
The table below lists competitors of Drugs Made In America Acquisition II Corp. Ordinary Shares ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Zhejiang Jianfeng Group Co Ltd
SHG:600668
|
$655.56 Million |
|
Mah Sing Group Bhd
KLSE:8583
|
$655.62 Million |
|
Sansec Technology Co. Ltd. A
SHG:688489
|
$655.64 Million |
|
Jiangxi Yuean Advanced Materials Co Ltd
SHG:688786
|
$655.68 Million |
|
Jiangsu Yueda Investment Co Ltd
SHG:600805
|
$654.94 Million |
|
Beijing Bayi Space LCD Technology Co Ltd
SHG:688181
|
$654.91 Million |
|
Welspun Enterprises Limited
NSE:WELENT
|
$654.54 Million |
|
NTG Nordic Transport Group A/S
CO:NTG
|
$654.46 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Drugs Made In America Acquisition II Corp. Ordinary Shares's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares Drugs Made In America Acquisition II Corp. Ordinary Shares's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2024-12-31 | $0.00 | $9.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Drugs Made In America Acquisition II Corp. Ordinary Shares utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-140.05K |
Industry Comparison
This section compares Drugs Made In America Acquisition II Corp. Ordinary Shares's net assets metrics with peer companies in the Shell Companies industry.
Industry Context
- Industry: Shell Companies
- Average net assets among peers: $150,605,478
- Average return on equity (ROE) among peers: 0.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) | $482.83 Million | 0.00% | 0.04x | $655.09 Million |
| Artius II Acquisition Inc. Class A Ordinary Shares (AACB) | $214.29 Million | 0.06% | 0.07x | $229.73 Million |
| Artius II Acquisition Inc. Units (AACBU) | $-60.27K | 0.00% | 0.00x | $269.37 Million |
| Ares Acquisition Corporation II (AACT) | $11.15K | -0.14% | 45.93x | $587.05 Million |
| AA Mission Acquisition Corp. (AAM) | $994.80 Million | 5.63% | 1.68x | $388.34K |
| Global Acquisitions Corporation (AASP) | $-106.61K | 0.00% | 0.00x | $15.42 Million |
| ABV Consulting Inc (ABVN) | $-341.70K | 0.00% | 0.00x | $461.96K |
| Averin Capital Acquisition Corp. Units (ACAAU) | $-48.38K | 0.00% | 0.00x | $1.00K |
| Atlantic Coastal Acquisition Corp II (ACAB) | $297.92 Million | 0.30% | 0.04x | $2.44 Million |
| Annabidiol Corp (ACBD) | $-111.66K | 0.00% | 0.00x | $14.44K |
| ACRO Biomedical Co Ltd (ACBM) | $-294.97K | 0.00% | 0.00x | $30.04K |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
Drugs Made In America Acquisition II Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2024 and is based in Fort Lauderdale, Florida.